Repercussions Of A Merger: TRU-015 Potentially Up For Grabs
This article was originally published in The Pink Sheet Daily
Change-of-control provision may return Phase IIb rheumatoid arthritis program to biotech developer. Would Pfizer pay (again) to be the partner?
You may also be interested in...
Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.
Firms forge ahead with rheumatoid arthritis program.
Private biotechs' growing dependence on an M&A exit and the more lively acquisition activity throughout the sector means change of control provisions are being far more heavily negotiated than in the past, and it's critical to understand how far-reaching these provisions could be for biotechs hoping for successful exits.